Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dexchlorpheniramine is a first-generation antihistamine and the S-enantiomer of chlorpheniramine. It acts as a competitive antagonist at histamine H1 receptors, blocking the effects of endogenous histamine and thereby reducing symptoms such as sneezing, runny nose, itching, watery eyes, hives, rashes, and other allergic manifestations. In addition to its antihistaminic activity, it has anticholinergic (drying) and sedative properties. It is indicated for the treatment of allergic conditions including rhinitis (allergic and vasomotor), conjunctivitis due to allergies or colds, mild urticaria/angioedema, dermatographism (hives from scratching), reactions to blood/plasma transfusions as adjunctive therapy with epinephrine in anaphylaxis or severe allergic reactions[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexchlorpheniramine.